 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | ? |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Eliminationhalf-life | ? |
| Excretion | ? |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.042.761 |
| Chemical and physical data | |
| Formula | C16H12Cl2N2O |
| Molar mass | 319.19 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cloroqualone is a quinazolinone-classGABAergic and is an analogue ofmethaqualone developed in the 1980s and marketed mainly in France and some other European countries. It hassedative andantitussive properties resulting from its agonist activity at the β subtype of theGABAa receptor andsigma-1 receptor, and was sold either alone or in combination with other ingredients as acough medicine. Cloroqualone has weaker sedative properties than methaqualone and was sold for its useful cough-suppressing effects, but was withdrawn from the French market in 1994 because of concerns about its potential for abuse and overdose.[1][2][3]
